SCHEMBL13626638

SCHEMBL13626638

CCN(c1cc(OC)ccc1[C@@H]1CCc2cc(O)ccc2C1)C(C)c1ccc(OCCN2CCC(C)CC2)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 6/20 0.44
ESR1 P03372 6/20 0.44
DRD2 P14416 2/20 0.34
HTR2A P28223 4/20 0.34
HTR2C P28335 4/20 0.34
HTR2B P41595 3/20 0.34
SIGMAR1 Q99720 1/20 0.33
MLNR O43193 1/20 0.33
NR1I2 O75469 1/20 0.33
NR3C1 P04150 1/20 0.33
CHRM2 P08172 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRA2A P08913 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CHRM1 P11229 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
CHRM3 P20309 1/20 0.33
SLC6A2 P23975 1/20 0.33
NPY1R P25929 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13626711 0.93 HTR2C (0.36) ESR2ESR1HTR2AHTR2CHTR2B
SCHEMBL13626639 0.88 ESR1 (0.47) ESR2ESR1DRD2DRD3
SCHEMBL227997 0.87 ESR1 (0.46) ESR2ESR1DRD2HTR2AHTR2C
SCHEMBL13626703 0.87 ESR1 (0.37) ESR2ESR1DRD2HTR2AHTR2C
SCHEMBL13626641 0.86 ESR1 (0.47) ESR2ESR1DRD2DRD3
SCHEMBL13626708 0.86 ESR1 (0.38) ESR2ESR1HTR2C
SCHEMBL13626584 0.86 ESR1 (0.56) ESR2ESR1DRD2DRD3
SCHEMBL13626585 0.86 ESR1 (0.49) ESR2ESR1DRD2DRD3
SCHEMBL13626640 0.86 ESR1 (0.46) ESR2ESR1DRD2DRD3
SCHEMBL13626662 0.86 ESR1 (0.42) ESR2ESR1DRD2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612114-B2 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed